Iovance Biotherapeutics (IOVA) Highlights Updated Clinical Data for Tumor Infiltrating Lymphocyte Therapy Lifileucel in Advanced Melanoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. HOOD
10. IBM

Go back to Iovance Biotherapeutics (IOVA) Highlights Updated Clinical Data for Tumor Infiltrating Lymphocyte Therapy Lifileucel in Advanced Melanoma

Iovance Presents Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at ASCO Scientific Program

May 29, 2020 8:02 AM EDT

Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up

36.4% Overall Response Rate (ORR) Maintained

SAN CARLOS, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today presented long-term interim data from Cohort 2 in the C-144-01 study of lifileucel in advanced melanoma during an oral session at the American Society of Clinical Oncologys (ASCO)... More